Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy

BACKGROUND: Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy. Production of extracellular adenosine, via CD73-mediated catabolism of AMP, contribu...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Turiello, Roberta, Capone, Mariaelena, Giannarelli, Diana, Morretta, Elva, Monti, Maria Chiara, Madonna, Gabriele, Mallardo, Domenico, Festino, Lucia, Azzaro, Rosa, Levesque, Mitchell P, Imhof, Laurence, Weide, Benjamin, Amaral, Teresa, Chevrier, Marc, Sucker, Antje, Rutkowski, Piotr, Schadendorf, Dirk, Lebbe, Celeste, Luke, Jason John, Wistuba-Hamprecht, Kilian, Dummer, Reinhard, Pinto, Aldo, Morello, Silvana, Ascierto, Paolo A
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2020
Pynciau:
Immunotherapy Biomarkers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7759961/
https://ncbi.nlm.nih.gov/pubmed/33361405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001689
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg